Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elpipodect (MK-8189) in Bipolar I Disorder
NCT06273774Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elpipodect in bipolar I disorder (6 arms), sponsored by Merck & Co. Primary endpoints: Adverse Events at 28 days and Discontinuation due to Adverse Event at 14 days. Started Apr 2024; status: completed.
02
Drugs
elpipodect
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT06273774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06273774.